Study finds limited drug benefit for long COVID fatigue, emphasizes multidisciplinary care

A large clinical trial published in The Lancet Infectious Diseases indicates that several repurposed drug treatments offer only modest, short-lived improvements for long COVID fatigue. While specialist supportive care alone showed meaningful benefits, adding drugs like colchicine or a famotidine-loratadine combination provided minimal additional gains. The findings reinforce the importance of comprehensive multidisciplinary management as the primary approach for long COVID.